The in-vivo diagnostic tool to personalize treatment of cancer patients, thereby improving precision, treatment outcome, and survival.
We need better methods to predict individual response to different types of medical treatments. In some cases, a treatment plan fails because only a subgroup of patients responds to that treatment. On the other hand, patients who do respond to the first-line treatment have an excellent 5-year survival rate.
With more than 200 different anti-cancer drugs on the market and a multitude of other treatment options (i.e., surgery, radiation therapy), patients who do not respond to current first-line treatment may benefit from a different drug, combination of drugs, or procedure.
Individualized treatment would identify and prioritize patients who will not respond to standard treatment and offer them alternative medical treatments or immediate surgery if this is an option for the specific tumor type.
BioReperia´s vision is to radically reduce cancer mortality by predicting the most efficient cancer treatments for each individual patient within a week, instead of the current wait time of 4-6 months.
Ask your questions or request an introductory call.